Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress

Fig. 2

Cyr61 and IL-6 levels in ascites of different (the early or advanced) stage of ovarian cancer patient and the correlation. In the patient with ovarian serous adenocarcinoma, ascites Cyr61 and IL-6 levels of the advanced stage (n = 52) were both higher than those of the early stage (n = 14). And the increased IL-6 expression was linearly related to Cyr61 level in malignant ascites

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us